30/4/2025, 3:49:03 pm

Italy’s Recordati Sees Tariff Volatility Fueling Dealmaking

Italian drugmaker Recordati SpA, backed by CVC Capital Partners, is actively seeking acquisitions amid market volatility and US tariff impacts, targeting rare diseases and specialty care areas. CEO Robert Koremans highlighted opportunities in the US, where smaller biotechs may face financial strain. Recordati aims to grow revenue to €3.2 billion by 2027, driven by acquisitions.